{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:51:18Z","timestamp":1791168678104,"version":"4.1.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","award":["202223-UGCES-22-GE-TAM-F SJSGC-792"],"award-info":[{"award-number":["202223-UGCES-22-GE-TAM-F SJSGC-792"]}],"id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11498-2","type":"journal-article","created":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T11:38:04Z","timestamp":1772365084000},"page":"7569-7582","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring molecular frameworks for modulating NLRP3-driven neuroinflammation in Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"30","author":[{"given":"Chandrasekaran Sahana","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarjith Thiyyar","family":"Kandy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giridharan","family":"Sivakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1912-1323","authenticated-orcid":false,"given":"Anand","family":"Vijayakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,1]]},"reference":[{"issue":"1","key":"11498_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","volume":"7","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Amieva H, Petersen RC, Ch\u00e9telat G, Holtzman DM, Hyman BT et al (2021) Alzheimer disease. Nat Rev Disease Primers 7(1):33. https:\/\/doi.org\/10.1038\/s41572-021-00269-y","journal-title":"Nat Rev Disease Primers"},{"key":"11498_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/diseases12060110","author":"CA Valdez-Gaxiola","year":"2024","unstructured":"Valdez-Gaxiola CA, Rosales-Leycegui F, Gaxiola-Rubio A, Moreno-Ortiz JM, Figuera LE (2024) Early- and late-onset Alzheimer\u2019s disease: Two sides of the same coin? Diseases. https:\/\/doi.org\/10.3390\/diseases12060110","journal-title":"Diseases"},{"issue":"2","key":"11498_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.12865\/chsj.50.02.02","volume":"50","author":"E Colita","year":"2024","unstructured":"Colita E, Mateescu VO, Olaru DG, Popa-Wagner A (2024) Cognitive decline in ageing and disease: risk factors, genetics and treatments. Curr Health Sci J 50(2):170\u2013180. https:\/\/doi.org\/10.12865\/chsj.50.02.02","journal-title":"Curr Health Sci J"},{"issue":"21","key":"11498_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232112924","volume":"23","author":"U Sehar","year":"2022","unstructured":"Sehar U, Rawat P, Reddy AP, Kopel J, Reddy PH (2022) Amyloid beta in aging and Alzheimer\u2019s disease. Int J Mol Sci 23(21):12924. https:\/\/doi.org\/10.3390\/ijms232112924","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11498_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02584-x","volume":"19","author":"RJ Boyd","year":"2022","unstructured":"Boyd RJ, Avramopoulos D, Jantzie LL, McCallion AS (2022) Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases. J Neuroinflammation 19(1):223. https:\/\/doi.org\/10.1186\/s12974-022-02584-x","journal-title":"J Neuroinflammation"},{"issue":"1","key":"11498_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03163-y","volume":"21","author":"S Lista","year":"2024","unstructured":"Lista S, Imbimbo BP, Grasso M, Fidilio A, Emanuele E, Minoretti P et al (2024) Tracking neuroinflammatory biomarkers in Alzheimer\u2019s disease: a strategy for individualized therapeutic approaches? J Neuroinflammation 21(1):187. https:\/\/doi.org\/10.1186\/s12974-024-03163-y","journal-title":"J Neuroinflammation"},{"key":"11498_CR7","doi-asserted-by":"publisher","first-page":"7825","DOI":"10.2147\/ijn.S444115","volume":"18","author":"Z Zhao","year":"2023","unstructured":"Zhao Z, Liu Y, Ruan S, Hu Y (2023) Current anti-amyloid-\u03b2 therapy for Alzheimer\u2019s disease treatment: from clinical research to nanomedicine. Int J Nanomedicine 18:7825\u20137845. https:\/\/doi.org\/10.2147\/ijn.S444115","journal-title":"Int J Nanomedicine"},{"issue":"5-6","key":"11498_CR8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s00508-024-02466-7","volume":"137","author":"E St\u00f6gmann","year":"2025","unstructured":"St\u00f6gmann E, Schmidt R (2025) Amyloid-beta antibody treatment in Alzheimer\u2019s disease. Wien Klin Wochenschr 137(5\u20136):182\u2013188. https:\/\/doi.org\/10.1007\/s00508-024-02466-7","journal-title":"Wien Klin Wochenschr"},{"key":"11498_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1391517","author":"M Amelimojarad","year":"2024","unstructured":"Amelimojarad M, Amelimojarad M, Cui X (2024) The emerging role of brain neuroinflammatory responses in Alzheimer\u2019s disease. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2024.1391517","journal-title":"Front Aging Neurosci"},{"key":"11498_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2024.1423139","author":"W Sun","year":"2024","unstructured":"Sun W, Gong J, Li S, Wang P, Han X, Xu C et al (2024) Bibliometric analysis of neuroinflammation and Alzheimer\u2019s disease. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2024.1423139","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"11498_CR11","doi-asserted-by":"publisher","first-page":"7124","DOI":"10.1007\/s12035-025-04758-z","volume":"62","author":"G Ayyubova","year":"2025","unstructured":"Ayyubova G, Madhu LN (2025) Microglial NLRP3 inflammasomes in Alzheimer\u2019s disease pathogenesis: from interaction with autophagy\/mitophagy to therapeutics. Mol Neurobiol 62(6):7124\u20137143. https:\/\/doi.org\/10.1007\/s12035-025-04758-z","journal-title":"Mol Neurobiol"},{"issue":"18","key":"11498_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810632","volume":"23","author":"L Zhang","year":"2022","unstructured":"Zhang L, Ai C, Bai M, Niu J, Zhang Z (2022) NLRP3 inflammasome\/pyroptosis: a key driving force in diabetic cardiomyopathy. Int J Mol Sci 23(18):10632. https:\/\/doi.org\/10.3390\/ijms231810632","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11498_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s40659-022-00404-3","volume":"55","author":"C Novoa","year":"2022","unstructured":"Novoa C, Salazar P, Cisternas P, Gherardelli C, Vera-Salazar R, Zolezzi JM et al (2022) Inflammation context in Alzheimer\u2019s disease, a relationship intricate to define. Biol Res 55(1):39. https:\/\/doi.org\/10.1186\/s40659-022-00404-3","journal-title":"Biol Res"},{"issue":"13","key":"11498_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cells14130994","volume":"14","author":"B Chhunchha","year":"2025","unstructured":"Chhunchha B, Kubo E, Lehri D, Singh DP (2025) NLRP3 inflammasome and inflammatory response in aging disorders: the entanglement of redox modulation in different outcomes. Cells 14(13):994. https:\/\/doi.org\/10.3390\/cells14130994","journal-title":"Cells"},{"key":"11498_CR15","doi-asserted-by":"crossref","unstructured":"Wen X, Yang H, Chen S, Xiao Z (2025). The research trends and hotspots of NLRP3 inflammasome in Alzheimer\u2019s disease: a bibliometric and visualization analysis","DOI":"10.1101\/2025.01.08.25320239"},{"issue":"8","key":"11498_CR16","doi-asserted-by":"publisher","first-page":"10792","DOI":"10.1007\/s12035-025-04918-1","volume":"62","author":"R Maurya","year":"2025","unstructured":"Maurya R, Sharma A, Naqvi S (2025) Decoding NLRP3 inflammasome activation in Alzheimer\u2019s disease: a focus on receptor dynamics. Mol Neurobiol 62(8):10792\u201310812. https:\/\/doi.org\/10.1007\/s12035-025-04918-1","journal-title":"Mol Neurobiol"},{"key":"11498_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1583886","author":"Z Li","year":"2025","unstructured":"Li Z, Gong C (2025) NLRP3 inflammasome in Alzheimer\u2019s disease: molecular mechanisms and emerging therapies. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2025.1583886","journal-title":"Front Immunol"},{"key":"11498_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.15788","author":"D Jha","year":"2023","unstructured":"Jha D, Bakker ENTP, Kumar R (2023) Mechanistic and therapeutic role of <scp>NLRP3<\/scp> inflammasome in the pathogenesis of Alzheimer\u2019s disease. J Neurochem. https:\/\/doi.org\/10.1111\/jnc.15788","journal-title":"J Neurochem"},{"issue":"1","key":"11498_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-021-00724-8","volume":"28","author":"SS Faria","year":"2021","unstructured":"Faria SS, Costantini S, de Lima VCC, de Andra VP, Rialland M, Cedric R et al (2021) Nlrp3 inflammasome-mediated cytokine production and pyroptosis cell death in breast cancer. J Biomed Sci 28(1):26. https:\/\/doi.org\/10.1186\/s12929-021-00724-8","journal-title":"J Biomed Sci"},{"key":"11498_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bbi.2013.05.011","volume":"33","author":"A del Rey","year":"2013","unstructured":"del Rey A, Balschun D, Wetzel W, Randolf A, Besedovsky HO (2013) A cytokine network involving brain-borne IL-1\u03b2, IL-1ra, IL-18, IL-6, and TNF\u03b1 operates during long-term potentiation and learning. Brain Behav Immun 33:15\u201323. https:\/\/doi.org\/10.1016\/j.bbi.2013.05.011","journal-title":"Brain Behav Immun"},{"key":"11498_CR21","doi-asserted-by":"publisher","DOI":"10.37349\/ei.2022.00048","author":"X Gao","year":"2022","unstructured":"Gao X, Zhang X, Sun Y, Dai X (2022) Mechanism of NLRP3 inflammasome activation and its role in Alzheimer\u2019s disease. Explor Immunol. https:\/\/doi.org\/10.37349\/ei.2022.00048","journal-title":"Explor Immunol"},{"issue":"2","key":"11498_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3233\/JAD-210660","volume":"84","author":"M Golzari-Sorkheh","year":"2021","unstructured":"Golzari-Sorkheh M, Brown CE, Weaver DF, Reed MA (2021) The NLRP3 inflammasome in the pathogenesis and treatment of Alzheimer\u2019s disease. J Alzheimers Dis 84(2):579\u2013598. https:\/\/doi.org\/10.3233\/JAD-210660","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"11498_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-024-01256-y","volume":"14","author":"L Zhang","year":"2024","unstructured":"Zhang L, Tang Y, Huang P, Luo S, She Z, Peng H et al (2024) Role of NLRP3 inflammasome in central nervous system diseases. Cell Biosci 14(1):75. https:\/\/doi.org\/10.1186\/s13578-024-01256-y","journal-title":"Cell Biosci"},{"key":"11498_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21030701","author":"PS Sung","year":"2020","unstructured":"Sung PS, Lin PY, Liu CH, Su HC, Tsai KJ (2020) Neuroinflammation and neurogenesis in Alzheimer\u2019s disease and potential therapeutic approaches. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21030701","journal-title":"Int J Mol Sci"},{"key":"11498_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1151185","volume":"14","author":"X Zheng","year":"2023","unstructured":"Zheng X, Wan J, Tan G (2023) The mechanisms of NLRP3 inflammasome\/pyroptosis activation and their role in diabetic retinopathy. Front Immunol 14:1151185. https:\/\/doi.org\/10.3389\/fimmu.2023.1151185","journal-title":"Front Immunol"},{"issue":"4","key":"11498_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41569-023-00946-3","volume":"21","author":"S Toldo","year":"2024","unstructured":"Toldo S, Abbate A (2024) The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nat Rev Cardiol 21(4):219\u2013237. https:\/\/doi.org\/10.1038\/s41569-023-00946-3","journal-title":"Nat Rev Cardiol"},{"key":"11498_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-025-03082-1","author":"L Zhou","year":"2025","unstructured":"Zhou L, Wu Z, Li Y, Xie Y, Sun L, Lin S et al (2025) Adult hippocampal neurogenesis-mediated cognitive behavior participates in stress resilience to anxiety and depression-like behaviors in postpartum dams. Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-025-03082-1","journal-title":"Mol Psychiatry"},{"key":"11498_CR28","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/ITT.S455881","volume":"13","author":"H Yan","year":"2024","unstructured":"Yan H, Wang W, Cui T, Shao Y, Li M, Fang L et al (2024) Advances in the understanding of the correlation between neuroinflammation and microglia in Alzheimer\u2019s disease. Immunotargets Ther 13:287\u2013304. https:\/\/doi.org\/10.2147\/ITT.S455881","journal-title":"Immunotargets Ther"},{"issue":"1","key":"11498_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04379-z","volume":"13","author":"M Bellut","year":"2021","unstructured":"Bellut M, Papp L, Bieber M, Kraft P, Stoll G, Schuhmann MK (2021) Nlpr3 inflammasome inhibition alleviates hypoxic endothelial cell death in vitro and protects blood\u2013brain barrier integrity in murine stroke. Cell Death Dis 13(1):20. https:\/\/doi.org\/10.1038\/s41419-021-04379-z","journal-title":"Cell Death Dis"},{"issue":"3","key":"11498_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/diseases11030089","volume":"11","author":"K Ramakrishna","year":"2023","unstructured":"Ramakrishna K, Nalla LV, Naresh D, Venkateswarlu K, Viswanadh MK, Nalluri BN et al (2023) Wnt-\u03b2 catenin signaling as a potential therapeutic target for neurodegenerative diseases: current status and future perspective. Diseases 11(3):89. https:\/\/doi.org\/10.3390\/diseases11030089","journal-title":"Diseases"},{"key":"11498_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbscr.2025.100123","volume":"18","author":"MI Smirnova","year":"2025","unstructured":"Smirnova MI, Quan N (2025) Modulation of adult hippocampal neurogenesis by interleukin 1 signaling. Neurobiol Sleep Circadian Rhythms 18:100123. https:\/\/doi.org\/10.1016\/j.nbscr.2025.100123","journal-title":"Neurobiol Sleep Circadian Rhythms"},{"issue":"1","key":"11498_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02964-x","volume":"20","author":"A Wu","year":"2023","unstructured":"Wu A, Zhang J (2023) Neuroinflammation, memory, and depression: new approaches to hippocampal neurogenesis. J Neuroinflammation 20(1):283. https:\/\/doi.org\/10.1186\/s12974-023-02964-x","journal-title":"J Neuroinflammation"},{"issue":"1","key":"11498_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11064-018-2517-8","volume":"44","author":"GA Prieto","year":"2019","unstructured":"Prieto GA, Tong L, Smith ED, Cotman CW (2019) TNF\u03b1 and IL-1\u03b2 but not IL-18 suppresses hippocampal long-term potentiation directly at the synapse. Neurochem Res 44(1):49\u201360. https:\/\/doi.org\/10.1007\/s11064-018-2517-8","journal-title":"Neurochem Res"},{"issue":"6","key":"11498_CR34","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202402644","volume":"7","author":"LV Walle","year":"2024","unstructured":"Walle LV, Said M, Paerewijck O, Bertoni A, Gattorno M, Linclau B et al (2024) Novel chemotype NLRP3 inhibitors that target the CRID3-binding pocket with high potency. Life Sci Alliance 7(6):e202402644. https:\/\/doi.org\/10.26508\/lsa.202402644","journal-title":"Life Sci Alliance"},{"issue":"6","key":"11498_CR35","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","volume":"15","author":"RC Coll","year":"2019","unstructured":"Coll RC, Hill JR, Day CJ, Zamoshnikova A, Boucher D, Massey NL et al (2019) MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol 15(6):556\u2013559. https:\/\/doi.org\/10.1038\/s41589-019-0277-7","journal-title":"Nat Chem Biol"},{"issue":"6","key":"11498_CR36","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41589-019-0278-6","volume":"15","author":"A Tapia-Abell\u00e1n","year":"2019","unstructured":"Tapia-Abell\u00e1n A, Angosto-Bazarra D, Mart\u00ednez-Banaclocha H, de Torre-Minguela C, Cer\u00f3n-Carrasco JP, P\u00e9rez-S\u00e1nchez H et al (2019) MCC950 closes the active conformation of NLRP3 to an inactive state. Nat Chem Biol 15(6):560\u2013564. https:\/\/doi.org\/10.1038\/s41589-019-0278-6","journal-title":"Nat Chem Biol"},{"issue":"1","key":"11498_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s10753-022-01730-0","volume":"46","author":"B Sharma","year":"2023","unstructured":"Sharma B, Satija G, Madan A, Garg M, Alam MM, Shaquiquzzaman M et al (2023) Role of NLRP3 inflammasome and its inhibitors as emerging therapeutic drug candidate for Alzheimer\u2019s disease: a review of mechanism of activation, regulation, and inhibition. Inflammation 46(1):56\u201387. https:\/\/doi.org\/10.1007\/s10753-022-01730-0","journal-title":"Inflammation"},{"key":"11498_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1422249","author":"IW Tengesdal","year":"2024","unstructured":"Tengesdal IW, Banks M, Dinarello CA, Marchetti C (2024) Screening NLRP3 drug candidates in clinical development: lessons from existing and emerging technologies. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1422249","journal-title":"Front Immunol"},{"key":"11498_CR39","unstructured":"https:\/\/patents.google.com\/patent\/WO2019166633A1\/en"},{"key":"11498_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02578","author":"A S\u00e1nchez-Fern\u00e1ndez","year":"2019","unstructured":"S\u00e1nchez-Fern\u00e1ndez A, Skouras DB, Dinarello CA, L\u00f3pez-Vales R (2019) OLT1177 (Dapansutrile), a selective NLRP3 inflammasome inhibitor, ameliorates experimental autoimmune encephalomyelitis pathogenesis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.02578","journal-title":"Front Immunol"},{"issue":"11","key":"11498_CR41","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1084\/jem.20171419","volume":"214","author":"H Jiang","year":"2017","unstructured":"Jiang H, He H, Chen Y, Huang W, Cheng J, Ye J et al (2017) Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med 214(11):3219\u20133238. https:\/\/doi.org\/10.1084\/jem.20171419","journal-title":"J Exp Med"},{"key":"11498_CR42","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05186051"},{"key":"11498_CR43","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04731324"},{"key":"11498_CR44","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04338997"},{"key":"11498_CR45","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05924243"},{"key":"11498_CR46","unstructured":"https:\/\/clinicaltrials.gov\/search?term=NCT06822517"},{"key":"11498_CR47","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT06836232"},{"key":"11498_CR48","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT06556173"},{"key":"11498_CR49","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT06047262?intr=NCT06047262&rank=1"},{"key":"11498_CR50","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT06771115"},{"key":"11498_CR51","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04886258"},{"key":"11498_CR52","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05658575"},{"key":"11498_CR53","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT06097663?term=DFV890&rank=4"},{"key":"11498_CR54","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04524858"},{"key":"11498_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113417","volume":"219","author":"C Zhang","year":"2021","unstructured":"Zhang C, Yue H, Sun P, Hua L, Liang S, Ou Y et al (2021) Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities. Eur J Med Chem 219:113417-. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113417","journal-title":"Eur J Med Chem"},{"issue":"6","key":"11498_CR56","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1021\/jp066496+","volume":"111","author":"D Kozlowski","year":"2007","unstructured":"Kozlowski D, Trouillas P, Calliste C, Marsal P, Lazzaroni R, Duroux JL (2007) Density functional theory study of the conformational, electronic, and antioxidant properties of natural chalcones. J Phys Chem A 111(6):1138\u20131145. https:\/\/doi.org\/10.1021\/jp066496+","journal-title":"J Phys Chem A"},{"key":"11498_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmcr.2022.100100","volume":"7","author":"P Thapa","year":"2023","unstructured":"Thapa P, Upadhyay SP, Singh V, Boinpelly VC, Zhou J, Johnson DK et al (2023) Chalcone: a potential scaffold for NLRP3 inflammasome inhibitors. Eur J Med Chem Rep 7:100100-. https:\/\/doi.org\/10.1016\/j.ejmcr.2022.100100","journal-title":"Eur J Med Chem Rep"},{"issue":"12","key":"11498_CR58","doi-asserted-by":"publisher","first-page":"7762","DOI":"10.1021\/acs.chemrev.7b00020","volume":"117","author":"C Zhuang","year":"2017","unstructured":"Zhuang C, Zhang W, Sheng C, Zhang W, Xing C, Miao Z (2017) Chalcone: a privileged structure in medicinal chemistry. Chem Rev 117(12):7762\u20137810. https:\/\/doi.org\/10.1021\/acs.chemrev.7b00020","journal-title":"Chem Rev"},{"issue":"4","key":"11498_CR59","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1021\/acsmedchemlett.1c00597","volume":"13","author":"R Zhang","year":"2022","unstructured":"Zhang R, Hong F, Zhao M, Cai X, Jiang X, Ye N et al (2022) New highly potent NLRP3 inhibitors: furanochalcone velutone F analogues. ACS Med Chem Lett 13(4):560\u2013569. https:\/\/doi.org\/10.1021\/acsmedchemlett.1c00597","journal-title":"ACS Med Chem Lett"},{"issue":"10","key":"11498_CR60","doi-asserted-by":"publisher","first-page":"2950","DOI":"10.1021\/acs.jnatprod.0c00478","volume":"83","author":"X Ma","year":"2020","unstructured":"Ma X, Zhao M, Tang MH, Xue LL, Zhang RJ, Liu L et al (2020) Flavonoids with inhibitory effects on NLRP3 inflammasome activation from Millettia velutina. J Nat Prod 83(10):2950\u20132959. https:\/\/doi.org\/10.1021\/acs.jnatprod.0c00478","journal-title":"J Nat Prod"},{"issue":"24","key":"11498_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25245960","volume":"25","author":"W-J Leu","year":"2020","unstructured":"Leu W-J, Chu J-C, Hsu J-L, Du C-M, Jiang Y-H, Hsu L-C et al (2020) Chalcones display anti-NLRP3 inflammasome activity in macrophages through inhibition of both priming and activation steps\u2014structure-activity-relationship and mechanism studies. Molecules 25(24):5960-. https:\/\/doi.org\/10.3390\/molecules25245960","journal-title":"Molecules"},{"key":"11498_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103748","volume":"98","author":"Y-L Tang","year":"2020","unstructured":"Tang Y-L, Zheng X, Qi Y, Pu X-J, Liu B, Zhang X et al (2020) Synthesis and anti-inflammatory evaluation of new chalcone derivatives bearing bispiperazine linker as IL-1\u03b2 inhibitors. Bioorg Chem 98:103748-. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103748","journal-title":"Bioorg Chem"},{"issue":"4","key":"11498_CR63","doi-asserted-by":"publisher","first-page":"410","DOI":"10.4062\/biomolther.2020.192","volume":"29","author":"HR Choi","year":"2021","unstructured":"Choi HR, Lim H, Lee JH, Park H, Kim HP (2021) Interruption of Helicobacter pylori<\/i> -induced NLRP3 inflammasome activation by chalcone derivatives. Biomol Ther (Seoul) 29(4):410\u2013418. https:\/\/doi.org\/10.4062\/biomolther.2020.192","journal-title":"Biomol Ther (Seoul)"},{"issue":"8","key":"11498_CR64","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1111\/acer.14120","volume":"43","author":"X Kong","year":"2019","unstructured":"Kong X, Wu G, Chen S, Zhang L, Li F, Shao T et al (2019) Chalcone derivative L6H21 reduces EtOH\u00a0+\u00a0LPS\u2010induced liver injury through inhibition of NLRP3 inflammasome activation. Alcohol Clin Exp Res 43(8):1662\u20131671. https:\/\/doi.org\/10.1111\/acer.14120","journal-title":"Alcohol Clin Exp Res"},{"key":"11498_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.rechem.2023.101139","volume":"6","author":"ND Mahurkar","year":"2023","unstructured":"Mahurkar ND, Gawhale ND, Lokhande MN, Uke SJ, Kodape MM (2023) Benzimidazole: a versatile scaffold for drug discovery and beyond \u2013 a comprehensive review of synthetic approaches and recent advancements in medicinal chemistry. Results Chem 6:101139-. https:\/\/doi.org\/10.1016\/j.rechem.2023.101139","journal-title":"Results Chem"},{"issue":"1","key":"11498_CR66","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1080\/14756366.2022.2110089","volume":"37","author":"J Caballero","year":"2022","unstructured":"Caballero J (2022) A new era for the design of TRPV1 antagonists and agonists with the use of structural information and molecular docking of capsaicin-like compounds. J Enzyme Inhib Med Chem 37(1):2169\u20132178. https:\/\/doi.org\/10.1080\/14756366.2022.2110089","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"5","key":"11498_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26051326","volume":"26","author":"RT Aroso","year":"2021","unstructured":"Aroso RT, Guedes RC, Pereira MM (2021) Synthesis of computationally designed 2,5(6)-benzimidazole derivatives via Pd-catalyzed reactions for potential E. coli DNA gyrase B inhibition. Molecules 26(5):1326. https:\/\/doi.org\/10.3390\/molecules26051326","journal-title":"Molecules"},{"issue":"13","key":"11498_CR68","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26133975","volume":"26","author":"S Gastaldi","year":"2021","unstructured":"Gastaldi S, Boscaro V, Gianquinto E, Sandall CF, Giorgis M, Marini E et al (2021) Chemical modulation of the 1-(piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazole-2-one scaffold as a novel NLRP3 inhibitor. Molecules 26(13):3975. https:\/\/doi.org\/10.3390\/molecules26133975","journal-title":"Molecules"},{"issue":"2","key":"11498_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22020213","volume":"22","author":"L Pan","year":"2017","unstructured":"Pan L, Hang N, Zhang C, Chen Y, Li S, Sun Y et al (2017) Synthesis and biological evaluation of novel benzimidazole derivatives and analogs targeting the NLRP3 inflammasome. Molecules 22(2):213. https:\/\/doi.org\/10.3390\/molecules22020213","journal-title":"Molecules"},{"issue":"3","key":"11498_CR70","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1021\/acschemneuro.0c00659","volume":"12","author":"M Imran","year":"2021","unstructured":"Imran M, Shah FA, Nadeem H, Zeb A, Faheem M, Naz S et al (2021) Synthesis and biological evaluation of benzimidazole derivatives as potential neuroprotective agents in an ethanol-induced rodent model. ACS Chem Neurosci 12(3):489\u2013505. https:\/\/doi.org\/10.1021\/acschemneuro.0c00659","journal-title":"ACS Chem Neurosci"},{"issue":"6","key":"11498_CR71","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/00207454.2022.2138382","volume":"134","author":"A Ahmed","year":"2024","unstructured":"Ahmed A, Khan A-u, Nadeem H, Imran M, Irshad N (2024) Pharmacological evaluation of newly synthesized benzimidazole derivative for anti-Alzheimer potential. Int J Neurosci 134(6):635\u2013651. https:\/\/doi.org\/10.1080\/00207454.2022.2138382","journal-title":"Int J Neurosci"},{"issue":"1","key":"11498_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74733-2","volume":"10","author":"H Goljani","year":"2020","unstructured":"Goljani H, Tavakkoli Z, Sadatnabi A, Masoudi-khoram M, Nematollahi D (2020) A new electrochemical strategy for the synthesis of a new type of sulfonamide derivatives. Sci Rep 10(1):17904. https:\/\/doi.org\/10.1038\/s41598-020-74733-2","journal-title":"Sci Rep"},{"key":"11498_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.chphi.2022.100147","volume":"6","author":"K Vibha","year":"2023","unstructured":"Vibha K, Prachalith NC, Annoji Reddy R, Ravikantha MN, Thipperudrappa J (2023) Computational studies on sulfonamide drug molecules by density functional theory. Chem Phys Impact 6:100147. https:\/\/doi.org\/10.1016\/j.chphi.2022.100147","journal-title":"Chem Phys Impact"},{"key":"11498_CR74","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.2022.36.S1.R3734","author":"H Blevins","year":"2022","unstructured":"Blevins H, Xu Y, Biby S, Zhang S (2022) Mechanistic insights of sulfonamide\u2010based NLRP3 inhibitors for the treatment of neurodegenerative diseases. FASEB J. https:\/\/doi.org\/10.1096\/fasebj.2022.36.S1.R3734","journal-title":"FASEB J"},{"key":"11498_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114468","volume":"238","author":"Y Xu","year":"2022","unstructured":"Xu Y, Xu Y, Blevins H, Guo C, Biby S, Wang X-Y et al (2022) Development of sulfonamide-based NLRP3 inhibitors: further modifications and optimization through structure-activity relationship studies. Eur J Med Chem 238:114468. https:\/\/doi.org\/10.1016\/j.ejmech.2022.114468","journal-title":"Eur J Med Chem"},{"issue":"19","key":"11498_CR76","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1021\/acschemneuro.4c00512","volume":"15","author":"S Biby","year":"2024","unstructured":"Biby S, Mondal P, Xu Y, Gomm A, Kaur B, Namme JN et al (2024) Functional characterization of an arylsulfonamide-based small-molecule inhibitor of the NLRP3 inflammasome. ACS Chem Neurosci 15(19):3576\u20133586. https:\/\/doi.org\/10.1021\/acschemneuro.4c00512","journal-title":"ACS Chem Neurosci"},{"key":"11498_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107263","volume":"146","author":"C Huang","year":"2024","unstructured":"Huang C, Liu J, Chen Y, Sun S, Kang T, Jiang Y et al (2024) Discovery of novel biphenyl-sulfonamide analogues as NLRP3 inflammasome inhibitors. Bioorg Chem 146:107263. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107263","journal-title":"Bioorg Chem"},{"issue":"23","key":"11498_CR78","doi-asserted-by":"publisher","first-page":"16141","DOI":"10.1021\/acs.jmedchem.3c01511","volume":"66","author":"S Sun","year":"2023","unstructured":"Sun S, Li Z, Huang C, Liu J, Yu Q, Jiang X et al (2023) Discovery of Novel 2,3-Dihydro-1 H -indene-5-sulfonamide NLRP3 Inflammasome Inhibitors Targeting Colon as a Potential Therapy for Colitis. J Med Chem 66(23):16141\u201316167. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01511","journal-title":"J Med Chem"},{"issue":"10","key":"11498_CR79","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1021\/acschemneuro.7b00124","volume":"8","author":"C Guo","year":"2017","unstructured":"Guo C, Fulp JW, Jiang Y, Li X, Chojnacki JE, Wu J et al (2017) Development and characterization of a hydroxyl-sulfonamide analogue, 5-chloro-N-[2-(4-hydroxysulfamoyl-phenyl)-ethyl]-2-methoxy-benzamide, as a novel NLRP3 inflammasome inhibitor for potential treatment of multiple sclerosis. ACS Chem Neurosci 8(10):2194\u20132201. https:\/\/doi.org\/10.1021\/acschemneuro.7b00124","journal-title":"ACS Chem Neurosci"},{"key":"11498_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1033003","author":"S-T Liang","year":"2022","unstructured":"Liang S-T, Chen C, Chen R-X, Li R, Chen W-L, Jiang G-H et al (2022) Michael acceptor molecules in natural products and their mechanism of action. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.1033003","journal-title":"Front Pharmacol"},{"issue":"3","key":"11498_CR81","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1021\/acs.jmedchem.6b00788","volume":"60","author":"PA Jackson","year":"2017","unstructured":"Jackson PA, Widen JC, Harki DA, Brummond KM (2017) Covalent modifiers: a chemical perspective on the reactivity of \u03b1,\u03b2-unsaturated carbonyls with thiols via hetero-Michael addition reactions. J Med Chem 60(3):839\u2013885. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00788","journal-title":"J Med Chem"},{"key":"11498_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcat.2020.110814","volume":"485","author":"RS Malkar","year":"2020","unstructured":"Malkar RS, Jadhav AL, Yadav GD (2020) Innovative catalysis in Michael addition reactions for C-X bond formation. Mol Catal 485:110814. https:\/\/doi.org\/10.1016\/j.mcat.2020.110814","journal-title":"Mol Catal"},{"key":"11498_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110229","volume":"119","author":"L Liu","year":"2023","unstructured":"Liu L, Feng L, Gao J, Hu J, Li A, Zhu Y et al (2023) Parthenolide targets NLRP3 to treat inflammasome-related diseases. Int Immunopharmacol 119:110229-. https:\/\/doi.org\/10.1016\/j.intimp.2023.110229","journal-title":"Int Immunopharmacol"},{"issue":"17","key":"11498_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127399","volume":"30","author":"Y Ou","year":"2020","unstructured":"Ou Y, Sun P, Wu N, Chen H, Wu D, Hu W et al (2020) Synthesis and biological evaluation of parthenolide derivatives with reduced toxicity as potential inhibitors of the NLRP3 inflammasome. Bioorg Med Chem Lett 30(17):127399-. https:\/\/doi.org\/10.1016\/j.bmcl.2020.127399","journal-title":"Bioorg Med Chem Lett"},{"issue":"24","key":"11498_CR85","doi-asserted-by":"publisher","first-page":"10366","DOI":"10.1021\/jm501072b","volume":"57","author":"M Cocco","year":"2014","unstructured":"Cocco M, Garella D, Di Stilo A, Borretto E, Stevanato L, Giorgis M et al (2014) Electrophilic warhead-based design of compounds preventing NLRP3 inflammasome-dependent pyroptosis. J Med Chem 57(24):10366\u201310382. https:\/\/doi.org\/10.1021\/jm501072b","journal-title":"J Med Chem"},{"issue":"1","key":"11498_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s13065-019-0531-9","volume":"13","author":"S Kakkar","year":"2019","unstructured":"Kakkar S, Narasimhan B (2019) A comprehensive review on biological activities of oxazole derivatives. BMC Chem 13(1):16. https:\/\/doi.org\/10.1186\/s13065-019-0531-9","journal-title":"BMC Chem"},{"issue":"12","key":"11498_CR87","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1021\/acsmedchemlett.3c00433","volume":"14","author":"Y Ohba","year":"2023","unstructured":"Ohba Y, Adachi K, Furukawa T, Nishimaru T, Sakurai K, Masuo R et al (2023) Discovery of novel NLRP3 inflammasome inhibitors composed of an oxazole scaffold bearing an acylsulfamide. ACS Med Chem Lett 14(12):1833\u20131838. https:\/\/doi.org\/10.1021\/acsmedchemlett.3c00433","journal-title":"ACS Med Chem Lett"},{"issue":"9","key":"11498_CR88","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.1021\/acs.jmedchem.4c00357","volume":"67","author":"M Zhao","year":"2024","unstructured":"Zhao M, Ye N, Liu L, Zhang RJ, Li N, Peng J et al (2024) Novel isoalantolactone-based derivatives as potent NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization. J Med Chem 67(9):7516\u20137538. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00357","journal-title":"J Med Chem"},{"issue":"1","key":"11498_CR89","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1021\/acs.jmedchem.3c01782","volume":"67","author":"Y Xu","year":"2024","unstructured":"Xu Y, Xu Y, Biby S, Kaur B, Liu Y, Bagdasarian FA et al (2024) Design and discovery of novel NLRP3 inhibitors and PET imaging radiotracers based on a 1,2,3-triazole-bearing scaffold. J Med Chem 67(1):555\u2013571. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01782","journal-title":"J Med Chem"},{"key":"11498_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117087","volume":"177","author":"L Xiao","year":"2024","unstructured":"Xiao L, Yan H, Yang S, Liu H, Li Y, Fang X et al (2024) Lindenane sesquiterpenoid dimers with NLRP3 inflammasome inhibitory activities from Chloranthus holostegius var. shimianensis. Biomed Pharmacother 177:117087-. https:\/\/doi.org\/10.1016\/j.biopha.2024.117087","journal-title":"Biomed Pharmacother"},{"key":"11498_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2024.107397","volume":"156","author":"S Gastaldi","year":"2024","unstructured":"Gastaldi S, Giordano M, Blua F, Rubeo C, Boscaro V, Femmin\u00f2 S et al (2024) Novel NLRP3 inhibitor INF195: low doses provide effective protection against myocardial ischemia\/reperfusion injury. Vasc Pharmacol 156:107397-. https:\/\/doi.org\/10.1016\/j.vph.2024.107397","journal-title":"Vasc Pharmacol"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11498-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11498-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11498-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T02:03:58Z","timestamp":1791165838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-026-11498-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":91,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["11498"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11498-2","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,1]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}